Advertisement

Topics

Latest "A Study Evaluating The Pharmacokinetics Of Ceftobiprole When Taken By Obese Patients" News Stories

16:18 EST 19th February 2019 | BioPortfolio

Here are the most relevant search results for "A Study Evaluating The Pharmacokinetics Of Ceftobiprole When Taken By Obese Patients" found in our extensive news archives from over 250 global news sources.

More Information about A Study Evaluating The Pharmacokinetics Of Ceftobiprole When Taken By Obese Patients on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about A Study Evaluating The Pharmacokinetics Of Ceftobiprole When Taken By Obese Patients for you to read. Along with our medical data and news we also list A Study Evaluating The Pharmacokinetics Of Ceftobiprole When Taken By Obese Patients Clinical Trials, which are updated daily. BioPortfolio also has a large database of A Study Evaluating The Pharmacokinetics Of Ceftobiprole When Taken By Obese Patients Companies for you to search.

Showing "Study Evaluating Pharmacokinetics Ceftobiprole When Taken Obese Patients" News Articles 1–25 of 35,000+

Tuesday 19th February 2019

$MRK Provides Update on KEYNOTE-240, a Phase 3 Study of KEYTRUDA® in Previously Treated Patients with Advanced Hepatocellular Carcinoma #HCC #Fail https://www.businesswire.com/news/home/20190219005993/en/Merck-Update-KEYNOTE-240-Phase-3-Study-KEYTRUDA%C2

$MRK Provides Update on KEYNOTE-240, a Phase 3 Study of KEYTRUDA® in Previously Treated Patients with Advanced Hepatocellular Carcinoma #HCC #Fail https://www.businesswire.com/news/home/20190219005993/en/Merck-Update-KEYNOTE-240-Phase-3-Study-KEYTRUDA%C2%AE …


Merck Provides Update on KEYNOTE-240, a Phase 3 Study of KEYTRUDA® (pembrolizumab) in Previously Treated Patients with Advanced Hepatocellular Carcinoma

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-240 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus best supportive care, for the treatment of patients with advanced hepatocellular carcinoma (HCC) who were previously treated with systemic therapy, did not meet its co-primar...

Nurse-led psychological intervention does not reduce PTSD symptoms in ICU patients

1. In this randomized clinical trial, nurse-led psychological interventions did not reduce PTSD risk at 6 months compared to care as usual for patients in the ICU. 2. There was no difference in anxiety or depression rates in patients who received psychological interventions. Evidence Rating Level: 1 (Excellent) Study Rundown: Up to 1 in 4 […] Source: 2 Minute Medicine


Men who can do 40 pushups have lower risk of heart problems: study https://nyp.st/2SJUwhh pic.twitter.com/odtEzIkXHs

Men who can do 40 pushups have lower risk of heart problems: study https://nyp.st/2SJUwhh  pic.twitter.com/odtEzIkXHs

Addition of IV acetaminophen with propofol or dexmedetomidine reduces risk of post-operative delirium in older patients undergoing cardiac surgery

1. In this randomized controlled trial, post-operative scheduled intravenous (IV) acetaminophen combined with propofol or dexmedetomidine reduced risk of post-operative delirium in older patients undergoing cardiac surgery compared to placebo. 2. The combination with IV acetaminophen also significantly reduced delirium duration, ICU length of stay, and breakthrough analgesia compared with placebo....

STAT Plus: Federal prosecutors are more aggressively pursuing drug makers for wayward programs that provide patients with free medications, copay assistance, or other help. https://buff.ly/2SdkVyy 

STAT Plus: Federal prosecutors are more aggressively pursuing drug makers for wayward programs that provide patients with free medications, copay assistance, or other help. https://buff.ly/2SdkVyy 

FDA Approves Merck’s Keytruda for the Adjuvant Treatment of Melanoma Patients with Lymph Node Involvement Following Complete Resection

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection based on results from the EORTC1325/KEYNOTE-054 tria...

FDA Grants Entrectinib Priority Review for NTRK+ Tumors and ROS1+ NSCLC

The FDA has granted a priority review designation to a new drug application for entrectinib as a treatment for select adult and pediatric patients with NTRK fusion–positive locally advanced or metastatic solid tumors, as well as patients with metastatic ROS1-positive non–small cell lung cancer.

Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain

Pfizer Inc. (NYSE: PFE) and Eli Lilly and Company (NYSE: LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab in patients with moderate-to-severe chronic low back pain (CLBP). In the study, treatment with tanezumab 10 mg met the primary endpoint, demonstrating a statistically significant improvement in pain at 16 weeks compared to placebo. …

FDA Grants Priority Review to Genentech’s Entrectinib for Treatment of Patients with NTRK Fusion-Positive Advanced Solid Tumors

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Applications (NDAs) andgranted Priority Review for entrectinib for the treatment of adult and pediatric patients with neurotrophic tropomyosin receptor kinase (NTRK) fusion...

Intercept could score first NASH drug approval on positive Phase III data

Shares of the New York-based company jumped nearly 20 percent Tuesday on news that the REGENERATE study of obeticholic acid showed strong improvement in NASH-related liver fibrosis.

Study finds wide variation between human cell lines used for research #NBTintheNews via @Yale https://news.yale.edu/2019/02/18/study-finds-wide-variation-between-human-cell-lines-used-research …

Study finds wide variation between human cell lines used for research #NBTintheNews via @Yale https://news.yale.edu/2019/02/18/study-finds-wide-variation-between-human-cell-lines-used-research …

Study Tests Preoperative Therapy for Easing Resection Burden in Rare Cancer

A recently launched clinical trial aims to improve outcomes and quality of life for patients with nasal and paranasal squamous cell carcinoma (NPNSCC), a rare type of head and neck cancer that is challenging to treat and carries significant morbidity.

Dr. Arta Farahmand Treats Gum Disease in Torrance, CA with Minimally Invasive Gum Surgery Alternative, LANAP® Laser Dentistry

Dr. Arta Farahmand is raising awareness for those showing symptoms of gum disease, like red, swollen or bleeding gums in Torrance, CA, about the benefits of LANAP® therapy. LANAP uses dental lasers to gently eliminate disease-causing bacteria, creating a healthy environment. TORRANCE, Calif. (PRWEB) February 19, 2019 Periodontist, Dr. Arta Farahmand, raises awareness for LANAP®, a minim...

Worcester Polytechnic Institute-Led Study: Pregnant Women Facing Weight Stigma See Decreased Physical and Mental Health

Women who have negative social encounters regarding their weight while pregnant or postpartum tend to show more depressive symptoms and retain weight WORCESTER, Mass. (PRWEB) February 19, 2019 In one of the first research studies focused on the impact of weight stigma in pregnant and postpartum women, a team led by a Worcester Polytechnic Institute professor found that women who experience weight...

CIRCULOGENE Names Anthony L. Schmidt, M.D., as Medical Director

CIRCULOGENE, advancing precision medicine through molecular genetics testing, has named Anthony L. Schmidt, M.D., F.A.C.P., as Medical Director. Dr. Schmidt will lead the laboratory’s precision medicine initiatives and work to educate the medical community about CIRCULOGENE’s molecular diagnostics capabilities and next-generation sequencing (N...

Study: How Plants Turned Into Thieves to Survive

NewsScientists have discovered that grasses are able to short cut evolution by taking genes from their neighbors.Contributed Author: 

Oral fluoxetine in the management of amblyopic patients aged between 10 and 40 years old: a randomized clinical trial

Cerveau Technologies, Inc. and Institut de Radiofarmacia Aplicada de Barcelona, S.L. Announce Agreement to Manufacture Investigational Tau Ligand, [18F]MK-6240

This week Institut de Radiofarmacia Aplicada de Barcelona, S.L. (IRAB), a leading producer of imaging biomarkers for use in clinical research, has signed an agreement that grants the company the right to manufacture [18F]MK-6240, a next generation investigational Positron Emission Tomography (PET) imaging agent. This will facilitate clinical studies assess...

Job Research Foundation Makes Scientific Advisory Board Appointments: Prof. Alain Fischer, MD as Chief Scientific Officer, Prof. Andrew R. Gennery, MD Named to Board

Job Research Foundation, which seeks to help find a cure for Job Syndrome by providing the scientific community with additional opportunities to further research into the rare immunodeficiency disorder, has announced the appointment of Dr. Alain Fischer as Chief Scientific Officer of the Foundation’s Scientific Advisory Board and the addition of Dr. Andrew R. Gennery to the Foundation’s Scient...

'Alarming' number of people received restricted fentanyl, study says: https://cnn.it/2DSUp8J pic.twitter.com/PftPfQl1j3

'Alarming' number of people received restricted fentanyl, study says: https://cnn.it/2DSUp8J  pic.twitter.com/PftPfQl1j3

Mark Hozza Named Chief Commercial Officer at BioInformatics Inc.

BioInformatics Inc. appoints Mark Hozza as Chief Commercial Officer to lead the life science research and advisory firm's sales organization. ARLINGTON, Va. (PRWEB) February 19, 2019 BioInformatics Inc., part of Science and Medicine Group, today announced the appointment of Mark Hozza as Chief Commercial Officer of the life science research and advisory firm. As the leader of the sales organi...

QS/1, Digital Pharmacist partner on patient convenience, communication

FRESH Study Results Suggest New Parameter to Strengthen qSOFA Risk Assessment for Septic Patients

Data analysis leveraging Cheetah Medical technology presented at the 48th Critical Care Congress in San Diego Cheetah Medical, a Massachusetts-based leader in non-invasive fluid management devices, today announced results of a sepsis data analysis leveraging Cheetah Medical technology. The findings were presented at the Society of Critical Care Medicin...

Only 8% Of Cancer Patients In The U.S. Participate In Clinical Trials https://www.forbes.com/sites/victoriaforster/2019/02/19/why-do-only-eight-percent-of-cancer-patients-in-the-u-s-participate-in-clinical-trials/ …

Only 8% Of Cancer Patients In The U.S. Participate In Clinical Trials https://www.forbes.com/sites/victoriaforster/2019/02/19/why-do-only-eight-percent-of-cancer-patients-in-the-u-s-participate-in-clinical-trials/ …


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks